STOCKS TELEGRAPH

Tag: NASD:ENVB

  • Enveric Biosciences (ENVB) Stock Gains Momentum In Pre-Hour Trading

    Enveric Biosciences (ENVB) Stock Gains Momentum In Pre-Hour Trading

    The stock value of Enveric Biosciences, Inc. (NASDAQ: ENVB) has significantly increased after the company announced the issue of a ground-breaking patent for its novel chemical series. ENVB’s stock rose 156.78% to $3.03 per share as of the most recent premarket session.

    Patent Issuance

    A significant milestone for the business was reached on January 14, 2025, when Enveric Biosciences received U.S. Patent No. 12,195,439 from the USPTO. Its recently created EVM401 Series is covered under the patent, “Cl-Substituted Isopropylamine Fused Heterocyclic Mescaline Derivatives.”

    The fact that this landmark patent is the first to be granted for the EVM401 series shows how dedicated Enveric is to developing its line of non-hallucinogenic drugs to treat difficult mental and neurological disorders.

    The EVM401 Series’s Potential for Innovation

    Enveric’s pipeline will be expanded with the EVM401 Series, which will bring novel non-hallucinogenic compounds that may be crucial in the treatment of addiction and neuropsychiatric conditions. Promising evidence from early research suggests that these mescaline derivative chemicals may have therapeutic uses since they show unique patterns of brain receptor activation.

    The substances exhibit interactions with a number of important neurological receptors, such as the dopamine transporter (DAT), the 5-HT2C receptor, and the α2A adrenergic receptor (ADRA2A).

    Treatment Consequences for Neuropsychiatric Conditions

    New treatment options for drug use disorders, anxiety, depression, ADHD, and opioid withdrawal may be provided by the chemicals of the EVM401 Series. Notably, the 5-HT2C receptor is becoming a crucial target in the treatment of neuropsychiatric disorders, whereas the ADRA2A receptor is well-known for its function in controlling the symptoms of opioid withdrawal.

    Strategic Development Pipeline Expansion for Enveric

    Enveric Biosciences is concentrating on getting ready for the Investigational New Drug (IND) application for EB-003 in accordance with its strategic direction. The company’s attempts to increase its pipeline and obtain more patents demonstrate its dedication to diversifying its medicinal solutions.

    Additionally, to further expand the company’s portfolio, Enveric’s wholly-owned subsidiary Akos Biosciences has signed two licensing agreements with Restoration Biologics LLC with the goal of developing cannabinoid-COX-2 conjugate medicines for the treatment of joint diseases.

  • Enveric (ENVB) Stock Rockets Up 130% On Heels Of Key Licensing Agreement

    Enveric (ENVB) Stock Rockets Up 130% On Heels Of Key Licensing Agreement

    Enveric Biosciences, Inc (NASDAQ: ENVB) stock is witnessing a remarkable surge in its market valuation today, with an impressive ascent of 133.75% to $1.94 observed in the latest market session. This notable upswing in Enveric’s stock price coincides with the announcement of a strategic licensing agreement.

    Enveric (ENVB) today inked three preliminary agreements with an undisclosed biotechnology firm, marking the initiation of negotiations for the out-licensing of three distinct categories of compounds. These compounds originate from Enveric’s extensive reservoir comprising over 1,000 innovative molecules, crafted through the utilization of the Company’s Psybrary platform and its proprietary computational chemistry and artificial intelligence (AI) drug discovery system (PsyAI).

    The terms outlined in the three agreements entail that the undisclosed licensee would secure exclusive, royalty-bearing global licenses for the development and sublicensing of the assets. Additionally, the agreements entail cash buyout options and prospective option rights concerning closely associated assets within Enveric’s portfolio.

    The licensee would shoulder the responsibility for all forthcoming preclinical and clinical developmental phases pertaining to pharmaceutical applications for both human and/or animal usage. Moreover, Enveric stands to potentially receive significant remunerations, including development and sales milestone payments and execution fees, amounting to a cumulative total of $200 million, subject to specific conditions.

    These conditions encompass the approval of investigational new drug (IND) applications and the completion of Phases I through III testing for the licensed products. Royalty rates, ranging from 2.5% to 10% on future sales, are contingent upon meeting predefined sales benchmarks.

    The compound classes covered under these agreements are derived from two of the seven portfolios of preclinical molecules recently unveiled by Enveric, with numerous other molecules and classes remaining open for further out-licensing opportunities.

    The plight of patients grappling with severe mental health conditions has persistently suffered from a lack of meaningful innovation. Enveric is poised with enthusiasm to advance several of the novel compounds engendered through its drug discovery engine.